Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/32229
Title: An activin-A/C chimera exhibits activin and myostatin antagonistic properties.
Authors: Donaldson C.;Fischer W.H.;Muenster U.;Harrison C.A.;Vale W.
Institution: (Muenster, Donaldson, Vale, Fischer) Clayton Foundation Laboratories for Peptide Biology, Salk Institute, San Diego, CA 92037, United States (Harrison) Prince Henry's Institute of Medical Research, Monash Medical Centre, Clayton, Vic. 3168, Australia (Fischer) Clayton Foundation Laboratories for Peptide Biology, Salk Institute, 10010 N. Torrey Pines Rd., San Diego, CA 92037, United States
Issue Date: 18-Oct-2012
Copyright year: 2005
Publisher: American Society for Biochemistry and Molecular Biology Inc. (9650 Rockville Pike, Bethesda MD 20814, United States)
Place of publication: United States
Publication information: Journal of Biological Chemistry. 280 (44) (pp 36626-36632), 2005. Date of Publication: 04 Nov 2005.
Abstract: Activins are involved in many physiological and pathological processes and, like other members of the transforming growth factor-beta superfamily, signal via type II and I receptor serine kinases. Ligand residues involved in type II receptor binding are located in the two anti-parallel beta strands of the TGF-beta proteins, also known as the fingers. Activin-A mutants able to bind ActRII but unable to bind the activin type I receptor ALK4 define ligand residues involved in ALK4 binding and could potentially act as antagonists. Therefore, a series of FLAG-tagged activin-A/C chimeras were constructed, in each of which eight residues in the wrist loop and helix region (A/C 46-53, 54-61, 62-69, and 70-78) were replaced. Additionally, a chimera was generated in which the entire wrist region (A/C 46-78) was changed from activin-A to activin-C. The chimeras were assessed for ActRII binding, activin bioactivity, as well as antagonistic properties. All five chimeras retained high affinity for mouse ActRII. Of these, only A/C 46-78 was devoid of significant activin bioactivity in an A3 Lux reporter assay in 293T cells at concentrations up to 40 nM. A/C 46-53, 54-61, 62-69, and 70-78 showed activity comparable with wild type activin-A. When tested for the ability to antagonize ligands that signal via activin type II receptors, such as activin-A and myostatin, only the A/C 46-78 chimera showed antagonism (IC50, 1-10 nM). Additionally, A/C 46-78 decreased follicle-stimulating hormone release from the LbetaT2 cell line and rat anterior pituitary cells in primary culture in a concentration-dependent manner. These data indicate that activin residues in the wrist are involved in ALK4-mediated signaling. The activin antagonist A/C 46-78 may be useful for the study and modulation of activin-dependent processes. © 2005 by The American Society for Biochemistry and Molecular Biology, Inc.
DOI: http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1074/jbc.M507236200
PubMed URL: 16129674 [http://www.ncbi.nlm.nih.gov/pubmed/?term=16129674]
ISSN: 0021-9258
URI: https://repository.monashhealth.org/monashhealthjspui/handle/1/32229
Type: Article
Appears in Collections:Articles

Show full item record

Page view(s)

4
checked on Sep 6, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.